Knight Therapeutics (TSE:GUD) Reaches New 12-Month High - Time to Buy?

Key Points

• Reached a new 52-week high — Knight Therapeutics traded as high as C$7.56 (last C$7.48) and was up about 1.2%, with the 50‑day and 200‑day moving averages at C$6.36 and C$6.10 respectively.
• Recent quarter showed C$0.09 EPS on C$133.2M revenue, but the company remains marginally unprofitable with a negative net margin (−1.19%) and negative return on equity (−0.70%); analysts forecast roughly C$0.10 EPS for the year.
• Balance-sheet and valuation mixed: market cap ~C$739M with healthy liquidity (quick ratio 1.79, current ratio 2.39) but very high debt‑to‑equity (10.15) and negative valuation metrics (trailing P/E −150.8, negative PEG).

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s share price hit a new 52-week high on Monday . The stock traded as high as C$7.56 and last traded at C$7.48, with a volume of 15167 shares. The stock had previously closed at C$7.45.

Knight Therapeutics Trading Up 1.2%

The company's fifty day moving average price is C$6.36 and its two-hundred day moving average price is C$6.10. The company has a quick ratio of 1.79, a current ratio of 2.39 and a debt-to-equity ratio of 10.15. The company has a market cap of C$739.18 million, a price-to-earnings ratio of -150.80, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.29.

Knight Therapeutics (TSE:GUD - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported C$0.09 EPS for the quarter. Knight Therapeutics had a negative return on equity of 0.70% and a negative net margin of 1.19%.The business had revenue of C$133.20 million for the quarter. Research analysts expect that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.